{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:24Z","timestamp":1793946504837,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006197","name":"Fonden til L\u00e6gevidenskabens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008218","name":"Gangsted Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008241","name":"Desir\u00e9e og Niels Ydes Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum AB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009457","name":"Region Sj\u00e6lland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eclinm.2026.104193","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:43:14Z","timestamp":1788964994000},"page":"104193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interferon-\u03b1 vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9829-3099","authenticated-orcid":false,"given":"Trine Alma","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-1297","authenticated-orcid":false,"given":"Dennis Lund","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3437-0897","authenticated-orcid":false,"given":"Lukas Frans","family":"Ocias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Weis","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Brabrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Friis","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Schjellerup","family":"Eickhardt-Dalb\u00f8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-4375","authenticated-orcid":false,"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-1658","authenticated-orcid":false,"given":"Daniel","family":"El Fassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Kj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Kielsgaard","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben A.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-5928","authenticated-orcid":false,"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Mourits-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0996-1812","authenticated-orcid":false,"given":"Marianne Tang","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-7826","authenticated-orcid":false,"given":"Vibe","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Lindholm","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Stentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn","family":"Starklint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"de Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-6708","authenticated-orcid":false,"given":"Thomas S.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2026.104193_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.eclinm.2026.104193_bib2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2026.104193_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104193_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41375-020-0849-2","article-title":"Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea","volume":"35","author":"Alvarez-Larr\u00e1n","year":"2021","journal-title":"Leukemia"},{"issue":"4 Pt 2","key":"10.1016\/j.eclinm.2026.104193_bib5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104193_bib6","first-page":"3065","article-title":"Pegylated interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Hematology"},{"issue":"32","key":"10.1016\/j.eclinm.2026.104193_bib7","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104193_bib8","article-title":"Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension","author":"Gisslinger","year":"2020","journal-title":"ASH Annu Meet Abstr"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104193_bib9","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.eclinm.2026.104193_bib10","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104193_bib11","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104193_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/10428194.2015.1049171","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","volume":"57","author":"Utke Rank","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.eclinm.2026.104193_bib15","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.eclinm.2026.104193_bib17","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104193_bib18","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib19","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2026.104193_bib20","series-title":"Stata Statistical Software: Release 16","year":"2019"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104193_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104193_bib22","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104193_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.2010.022178","article-title":"Hydroxyurea induced oscillations in twelve patients with polycythemia vera","volume":"95","author":"Tauscher","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2155-9864.1000157","article-title":"The mean corpuscular volume and hydroxyurea in Brazilian patients with sickle cell anemia: a surrogate marker of compliance","volume":"4","author":"Clarisse Lopes de Castro Lobo","year":"2013","journal-title":"J Blood Disord Transfus"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70137","article-title":"Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV)","volume":"9","author":"Kiladjian","year":"2025","journal-title":"Hemasphere"},{"issue":"19","key":"10.1016\/j.eclinm.2026.104193_bib26","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.eclinm.2026.104193_bib27","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104193_bib28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ajh.23554","article-title":"World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations\u2014The Danish experience","volume":"88","author":"Madelung","year":"2013","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104193_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41375-022-01773-0","article-title":"Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients","volume":"37","author":"Ryou","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104193_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.eclinm.2026.104193_bib31","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2020008109","article-title":"The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms","volume":"137","author":"Hasselbalch","year":"2021","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.eclinm.2026.104193_bib32","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2019-126164","article-title":"Genomic profiling of a phase III clinical trial of interferon versus hydroxyurea in MPN patients reveals mutation-specific and treatment-specific patterns of response","volume":"134","author":"Knudsen","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104193_bib33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.2024027528","article-title":"DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera","volume":"146","author":"Abu-Zeinah","year":"2025","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:50:08Z","timestamp":1793944208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"alternative-id":["S2589537026004463"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104193","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-\u03b1 vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104193"}}